Premium
P‐015: A responder analysis of MPC‐7869 (tarenflurbil), a selective Aβ42‐lowering agent, in mild Alzheimer's disease (AD): Analysis from a phase 2 study of up to 24 months of treatment
Author(s) -
Zavitz Kenton H.,
Hendrix Suzanne,
Laughlin Mark,
Swabb Edward
Publication year - 2007
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2007.04.231
Subject(s) - placebo , medicine , randomized controlled trial , randomization , dose , clinical trial , clinical endpoint , physical therapy , pathology , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom